Sugi Predict

Sugi Predict / Targets / IDH1

IDH1

Isocitrate dehydrogenase [NADP] cytoplasmic · O75874 · IDH1 on Sugi Atlas →

106,462 patent compounds predicted against IDH1, 49,873 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL359876 SCHEMBL359876 0.64 20/20
Piroctone Piroctone (SCHEMBL3588) 0.50 19/20
Piroctone Piroctone (SCHEMBL2843) 0.43 18/20
Piroctone Piroctone (SCHEMBL457354) 0.43 18/20
Rilopirox Rilopirox (SCHEMBL219251) 0.69 17/20
SCHEMBL371213 SCHEMBL371213 0.67 17/20
SCHEMBL371214 SCHEMBL371214 0.67 17/20
SCHEMBL371215 SCHEMBL371215 0.67 17/20
SCHEMBL359676 SCHEMBL359676 0.78 16/20
SCHEMBL360507 SCHEMBL360507 0.78 16/20
SCHEMBL367882 SCHEMBL367882 0.67 16/20
SCHEMBL195830 SCHEMBL195830 0.41 16/20
SCHEMBL360556 SCHEMBL360556 1.00 15/20
SCHEMBL370245 SCHEMBL370245 0.85 15/20
SCHEMBL369011 SCHEMBL369011 0.81 15/20
SCHEMBL361399 SCHEMBL361399 0.67 15/20
SCHEMBL196253 SCHEMBL196253 0.52 15/20
SCHEMBL369403 SCHEMBL369403 0.83 14/20
SCHEMBL361617 SCHEMBL361617 0.79 14/20
SCHEMBL360503 SCHEMBL360503 0.64 14/20

Clinical trials — most relevant to IDH1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia PHASE3RECRUITING
Glutamate for Metabolic Intervention in Coronary Surgery PHASE3COMPLETED
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy PHASE2SUSPENDED
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Phase 2 Study of IDH305 in Low Grade Gliomas PHASE2WITHDRAWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas PHASE2COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma PHASE1/PHASE2RECRUITING
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma PHASE2WITHDRAWN
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations PHASE2SUSPENDED
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy PHASE2ACTIVE_NOT_RECRUITING
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation PHASE1COMPLETED
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation PHASE1COMPLETED
Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy nanUNKNOWN
Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma nanNOT_YET_RECRUITING
Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas nanCOMPLETED
Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas nanRECRUITING
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients nanUNKNOWN
Surgical Management of Low Grade Glioma nanNOT_YET_RECRUITING
Diagnostic and Therapeutic Targets in Cartilaginous Tumours nanRECRUITING
Non Invasive IDentification of Gliomas With IDH1 Mutation nanCOMPLETED
Radiomics-Based Visualization and Quantitative Validation of IDH1 Heterogeneity in Gliomas nanACTIVE_NOT_RECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
Monitoring of Neurological Symptoms, Treatment Tolerance, and Quality of Life Using the Resilience PRO Electronic Patient-reported Outcome Application in Patients With IDH-mutated Glioma nanNOT_YET_RECRUITING
Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML nanCOMPLETED
[18F] FDOPA PET Imaging in Glioma: Feasibility Study for PET Guided Brain Biopsy nanUNKNOWN
Revision of the EORTC QLQ-BN20 Questionnaire nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a IDH1 binder may also engage these)

ProteinNameSimilarity
Q5R9C5 — 1.000 Q5R9C5 →
Q6XUZ5 — 1.000 Q6XUZ5 →
Q9Z2K8 — 1.000 Q9Z2K8 →
O13294 — 1.000 O13294 →
P9WKL1 — 1.000 P9WKL1 →
P56574 — 1.000 P56574 →
Q9Z2K9 — 1.000 Q9Z2K9 →
Q9XSG3 — 1.000 Q9XSG3 →
P41562 — 1.000 P41562 →
P33198 — 1.000 P33198 →
O88844 — 0.999 O88844 →
Q75JR3 — 0.999 Q75JR3 →
Q4R502 — 0.998 Q4R502 →
Q9SLK0 — 0.997 Q9SLK0 →
IDH2 Isocitrate dehydrogenase [NADP], mitochondrial 0.997 landscape →
P41939 — 0.997 P41939 →
P21954 — 0.997 P21954 →
O14254 — 0.997 O14254 →
Q04467 — 0.997 Q04467 →
P50217 — 0.997 P50217 →
O13285 — 0.996 O13285 →
P54071 — 0.995 P54071 →
P53982 — 0.994 P53982 →
P50215 — 0.993 P50215 →
P32112 — 0.993 P32112 →
Q07RX1 — 0.993 Q07RX1 →
Q2SLT4 — 0.993 Q2SLT4 →
Q5SCV9 — 0.993 Q5SCV9 →
B8DR41 — 0.993 B8DR41 →
P56647 — 0.993 P56647 →